Expertise in
17
conditions

Dr. Rajneesh D. Nath

Hematology
UMass Memorial Children's Medical Center
55 Lake Ave N, 
Worcester, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
34 Years of Experience
Expertise in
17
conditions
UMass Memorial Children's Medical Center
55 Lake Ave N, 
Worcester, MA 

Overview

Rajneesh Nath is a Hematologist practicing medicine in Worcester, Massachusetts. He has been practicing medicine for over 34 years.

Dr. Nath is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Multiple Myeloma, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 37 peer reviewed articles and participating in 7 clinical trials. Dr. Nath is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MA

Hospital Affiliations

Community Medical Center
Robert Wood Johnson University Hospital
Banner Gateway Medical Center

Languages Spoken

English
Hindi
Punjabi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Fallon

Accepted plan types not found. Please verify directly with the provider.

Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MercyCare
  • EPO
  • HMO
Oscar
  • EPO
  • HMO
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

UMass Memorial Children's Medical Center
55 Lake Ave N, Worcester, MA 01655
Other Locations
Banner Family Pharmacy-Md Anderson
2946 E Banner Gateway Dr, Gilbert, AZ 85234

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: July 06, 2026
Intervention Type: Drug
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Enrollment Status: Active_not_recruiting
Publish Date: July 06, 2026
Intervention Type: Biological
Study Drugs: Lisocabtagene Maraleucel, Ibrutinib
Study Phase: Phase 1/Phase 2
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Enrollment Status: Terminated
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Study Phase: Phase 3
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Enrollment Status: Completed
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Pevonedistat, Venetoclax, Azacitidine
Study Phase: Phase 2
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: June 16, 2021
Intervention Type: Drug
Study Drugs: Rigosertib, Azacitidine
Study Phase: Phase 1/Phase 2
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: September 13, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

37 Total Publications

Unit culture and respectful care in obstetric care settings: a qualitative concept elicitation study.
Unit culture and respectful care in obstetric care settings: a qualitative concept elicitation study.
Journal: Frontiers in global women's health
Published: March 18, 2026
Similar Doctors
Expertise in
19
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Expertise in
19
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (33.5 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Dubois is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Dubois is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Embryonal Tumor with Multilayered Rosettes, Neuroblastoma, and Osteosarcoma. Dr. Dubois is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (33.5 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Corey Cutler is a Hematologist practicing medicine in Boston, Massachusetts. Dr. Cutler is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Graft. Dr. Cutler is currently accepting new patients.

Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required

Rhode Island Hospital

593 Eddy St, 
Providence, RI 
 (37.0 miles away)
401-444-5435
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Adam Olszewski is a Hematologist practicing medicine in Providence, Rhode Island. Dr. Olszewski is highly rated in 26 conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Marginal Zone Lymphoma (MZL), Non-Hodgkin Lymphoma, Splenectomy, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Rajneesh D. Nath

How do I make an appointment with Dr. Rajneesh D. Nath?

You can book an appointment with Dr. Rajneesh D. Nath by calling their office at 774-442-3903. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rajneesh D. Nath a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rajneesh D. Nath is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rajneesh D. Nath specialize in?

While Dr. Rajneesh D. Nath is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Rajneesh D. Nath participate in research or clinical trials?

Yes. Dr. Rajneesh D. Nath has published 37 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Rajneesh D. Nath's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rajneesh D. Nath accept my insurance?

Dr. Rajneesh D. Nath accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 774-442-3903 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nath's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile